転移性脳腫瘍　診断・治療・管理マニュアル

出版社： メディカ出版
著者：
発行日： 2014-12-01
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784840450072
電子書籍版： 2014-12-01 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

8,800 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,800 円(税込)

購入する

商品紹介

治療、管理に難渋する転移性脳腫瘍のすべてがわかる完全マニュアル。分野のエキスパートが実臨床に即して具体的かつ平易に解説しており、明日から現場で使える一冊となっている。腫瘍内科・外科、神経内科、脳神経外科、放射線科等の医師、がん認定看護師に最適。

目次

  • 転移性脳腫瘍　診断・治療・管理マニュアル

    ―目次―

    第1章　転移性脳腫瘍の概要
    第2章　転移性脳腫瘍の診断
    第3章　転移性脳腫瘍の治療
    第4章　髄膜がん腫症の治療
    第5章　中枢神経系のがん救急
    第6章　がん種別における転移性脳腫瘍の特徴
    第7章　転移性脳腫瘍の緩和医療
    第8章　転移性脳腫瘍の治療指針

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 転移性脳腫瘍の概要

P.12 掲載の参考文献
1) 国立がん研究センターがん対策情報センター : がん情報サービス. 2014年のがん統計予測. (http://ganjoho.jp/public/statistics/pub/short_pred.html)
 
2) 国立がん研究センターがん対策情報センター : 2012人口動態統計. 厚生労働省大臣官房統計情報部編. 2012
 
3) 国立がん研究センターがん対策情報センター : 全国がん罹患モニタリング集計 2010年罹患数・率報告. 2014
 
4) 国立がん研究センターがん対策情報センター : がん統計研究部. 院内がん登録室. がん診療連携拠点病院院内がん登録全国集計2011年全国集計報告書. 2013
 
5) Barnholtz-Sloan JS, Sloan AE, Davis FG, et al : Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 : 2865-72, 2004
PubMed
6) Schouten LJ, Rutten J, Huveneers HA, et al : Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94 : 2698-705, 2002
 
7) Soffietti R, Ruda R, Mutani R : Management of brain metastases. J Neurol 249 : 1357-69, 2002
PubMed
8) Committee of Brain Tumor Registry of Japan. Report of brain tumor registry of Japan (2001-2004). 13th edition. Neurol Med Chir (Tokyo) 54 (Suppl 1) : 1-102, 2014
 
9) Glantz MJ, Jaeckle KA, Chamberlain MC, et al : A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5 : 3394-402, 1999
PubMed
10) Glantz MJ, Cole BF, Forsyth PA, et al : Practice parameter : anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 : 1886-93, 2000
 
11) Gaspar L, Scott C, Rotman M, et al : Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 : 745-51, 1997
PubMed
12) Sneed PK, Suh JH, Goetsch SJ, et al : A multiinstitutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 53 : 519-26, 2002
PubMed
13) Agboola O, Benoit B, Cross P, et al : Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys 42 : 155-9, 1998
PubMed
14) Arita H, Narita Y, Miyakita Y, et al : Risk factors for early death after surgery in patients with brain metastases : reevaluation of the sindications for and role of surgery. J Neurooncol 116 : 145-52, 2014
PubMed
15) Sperduto PW, Chao ST, Sneed PK, et al : Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases : a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77 : 655-61, 2010
PubMed

第2章 転移性脳腫瘍の診断

P.24 掲載の参考文献
1) Hinchey J, Chaves C, Appignani B : A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 : 494-500, 1996
 
P.38 掲載の参考文献
1) 石岡久和, 蓮尾金博, 三原太 : 脳・脊髄. 癌の臨床 51 : 845-55, 2005
Medical*Online
2) 高橋英明, 宇塚岳夫, 吉田誠一 : 転移性脳腫瘍手術のパラダイムシフト-この10年間の変遷-. 県立がんセンター医誌 50 : 29-33, 2011
 
3) 野口智幸, 西原正志, 入江裕之, 他 : 原発性腫瘍と転移性脳腫瘍. 臨床画像 25 : 1226-33, 2009
Medical*Online
4) 田部井勇助, 宮本信吾, 鈴木一郎, 他 : 転移性脳腫瘍の集学的治療. 癌と化学療法 40 : 1288-94, 2013
Medical*Online
5) 成田善孝 : 頭蓋内圧亢進, 10-4 (大江裕一郎, 新海哲, 高橋俊二編 : がん救急マニュアル. メディカルビュー社, 東京, 2011)
 
6) 平戸純子, 中里洋一 : 放射線照射による中枢神経の障害. 病理と臨床 19 : 161-6, 2001
Medical*Online
7) 田岡俊昭 : MRによる脳腫瘍の機能画像診断. 映像情報Medical 43 : 64-73, 2011
Medical*Online
8) 渡會文果, 鹿戸将史, 細矢貴亮 : 脳腫瘍の治療後変化. 臨床画像 27 : 1430-5, 2011
Medical*Online
9) 高橋英明 : 固形癌における髄膜癌腫症の臨床. 県立がんセンター新潟病院医誌 52 : 60-6, 2013
Medical*Online
10) 橋詰良夫 : 【外科病理における神経病理 : 腫瘍・てんかん】脳および脊髄における転移性腫瘍の実態. 病理と臨床 25 : 984-9, 2007
Medical*Online
11) 野口智幸, 吉浦敬, 樋渡昭雄, 他 : 脳・脊髄. 臨床画像 23 : 726-33, 2007
Medical*Online

第3章 転移性脳腫瘍の治療

P.44 掲載の参考文献
1) Committee of Brain Tumor Registry of Japan. Report of brain tumor registry of Japan (2001-2004). 13th edition. Neurol Med Chir (Tokyo) 54 (Suppl 1) : 1-102, 2014
 
P.51 掲載の参考文献
1) Okuda T, Kataoka K, Yabuuchi T, et al : Fluorescence-guided surgery of metastatic brain tumors using fluorescein sodium. J Clin Neurosci 17 : 118-21, 2010
PubMed
2) Modha A, Shepard SR, Gutin PH, et al : Surgery of brain metastases--is there still a place for it? J Neurooncol 75 : 21-9, 2005
 
3) Lieu AS, Hwang SL, Howng SL, et al : Brain tumors with hemorrhage. J Formos Med Assoc 98 : 365-7, 1999
PubMed
4) Sawaya R, Hammoud M, Schoppa D, et al : Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42 : 1044-55, 1998
 
5) Paek SH, Audu PB, Sperling MR, et al : Reevaluation of surgery for the treatment of brain metastases : review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 56 : 1021-34, 2005
PubMed
P.54 掲載の参考文献
1) Ratcheson RA, Ommaya AK : Experience with the subcutaneous cerebrospinal-fluid reservoir. Preliminary report of 60 cases. N Engl J Med 279 : 1025-31, 1968
 
2) Sandberg DI, Bilsky MH, Souweidane MM, et al : Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47 : 49-55, 2000
PubMed
P.59 掲載の参考文献
1) Omuro AMP, Lallana EC, Billsky MH, et al : Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64 : 1625-7, 2005
 
P.72 掲載の参考文献
1) JASTROデータベース委員会. 全国放射線治療施設の2010年定期構造調査報告. 日本放射線腫瘍学会ホームページより
 
2) Gaspar LE, Scott C, Rotman M, et al : Recursive partitioning analysis ( RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 : 745-51, 1997
 
3) Gaspar LE, Scott C, Murray K, et al : Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47 : 1001-6, 2000
PubMed
4) Sperduto PW, Berkey B, Gaspar LE, et al : A new prognostic index and comparison to three other indices for patients with brain metastases : an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70 : 510-4, 2008
 
5) Andrews DW, Scott CB, Sperduto PW, et al : Whole brain radiation therapy with and without stereotactic radiosurgery boost for patients with one to three brain metastases : Phase III results of the RTOG9508 randomised trial. Lancet 363 : 1665-72, 2004
PubMed
6) Buatti JM, Friedman WA, Meeks SL, et al : RTOG 90-05 : the real conclusion. Int J Radiat Oncol Biol Phys 47 : 269-71, 2000
PubMed
7) Aoyama H, Shirato H, Tago M, et al : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 : 2483-91, 2006
PubMed
8) Aoyama H, Tago M, Kato N, et al : Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68 : 1388-95, 2007
PubMed
9) Patchell RA, Tibbs PA, Regine WF, et al : Postoperative radiotherapy in the treatment of single metastases to the brain : a randomized trial. JAMA 280 : 1485-9, 1998
 
10) Grosshans DR, Meyers CA, Allen PK F, et al : Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation. Cancer 112 : 589-95, 2008
 
11) Kocher M, Soffietti R, Abacioglu U, et al : Adjuvant whole-brain radiotherapy versus observation after radiosurgery ir surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study. J Clin Oncol 29 : 134-41, 2011
 
12) Kickingereder P, Dorn F, Blau T, et al : Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis : case report and review of the literature. Radiation Oncol 52 : 2013
PubMed
13) Mitsuya K, Nakasu Y, Horiguchi S, et al : Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol 99 : 81-88, 2010
PubMed
14) Tsuyuguchi N, Sunada I, Iwai Y, et al : Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery : is a differential diagnosis Possible? J Neurosurg 98 : 1056-64, 2003
PubMed
15) Kano H, Kondziolka D, Lobato-Polo J, et al : T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurg 66 : 486-492, 2010
 
16) 宮武伸一, 古瀬元雅 : 脳放射線壊死の成因と治療 : 高度医療 (第3項先進医療) の申請. 脳外誌 21 : 472-480, 2012
 
P.80 掲載の参考文献
1) Postmus PE, Brambilla E, Chansky K, et al : The IASLC Lung Cancer Staging Project : proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol 2 : 686-93, 2007
 
2) Barlesi F, Gervais R, Lena H, et al : Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases : a multicenter phase II trial (GFPC 07-01). Ann Oncol 11 : 2466-70, 2011
PubMed
3) Lee DH, Han JY, Kim HT, et al : Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study. Cancer 113 : 143-9, 2008
PubMed
4) Niho S, Kunitoh H, Nokihara H, et al : Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous nonsmall-cell lung cancer. Lung Cancer 76 : 362-7, 2012
PubMed
5) Besse B, Le Moulec S, Senellart H, et al : Final overall surviva (l OS) results of a noncomparative phase II study of bevacizumab (B) plus firstline chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (NSNSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN). J Clin Oncol 31 (suppl ; abstr 8059), 2013
 
6) Mok TS, Wu YL, Thongprasert S, et al : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 : 947-57, 2009
 
7) Takano T, Fukui T, Ohe Y, et al : EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma : a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26 : 5589-95, 2008
PubMed
8) Mitsudomi T, Morita S, Yatabe Y, et al : Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405) : an open label, randomised phase 3 trial. Lancet Oncol 11 : 121-8, 2010
PubMed
9) Park SJ, Kim HT, Lee DH, et al : Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77 : 556-60, 2012
PubMed
10) Shaw AT, Kim DW, Nakagawa K, et al : Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 : 2385-94, 2013
PubMed
11) Kaneda H, Okamoto I, Nakagawa K : Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive nonsmall-cell lung cancer. J Thorac Oncol 8 : e32-33, 2013
 

第4章 髄膜がん腫症の治療

P.90 掲載の参考文献
1) Omuro AM, Kris MG, Millar VA : High incidence of Disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer : 2344-8, 2005
 
2) 井内俊彦 : 髄膜がん腫症の診断と治療. 日本臨牀増刊号 新時代の脳腫瘍学 診断治療の最前線. 598-602, 2010
 
3) Yi HG, Kim HJ, Kim YJ : Epidermal growth factor recepto (r EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 65 : 80-4, 2008
PubMed
4) Zagouri F, Sergentanis TN, Bartsch R : Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer : a systematic review and pooled analysis. Breast Cancer Res Treat 139 : 13-22, 2013
PubMed
5) Omuro AM, Lallana EC, Bilsky MH : Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 64 : 1625-7, 2005
PubMed
6) Chamberlain MC : Neoplastic meningitis. Neurologist 12 : 179-87, 2006
PubMed
7) Lee SJ, Lee JI, Nam DH : Leptomeningeal carcinomatosis in non-small-cell lung cancer patients. Inpact on survival and correlated prognostic factors. J Thoracic Oncol 8 : 185-91, 2013
 
8) Jung TY, Chung WK, Oh IJ : The prognostic significance of surgically treated hydrocephalus in leptomeningeal metastases. Clin Neurol Neurosurg 119 : 80-3, 2014
PubMed
9) Kasari S, Batchelor TT : Leptomenigeal metastases. Neurol Clin North Am 21 : 25-66, 2003
 
10) Nakamura Y, Takahashi T, Tsuya A : Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis. Anticancer Res 32 : 1811-6, 2012
PubMed
11) Chamberlain MC, Junk L : Defining patients at risk for neoplastic meningitis : what parameters can be used to determine who should be treated? Expart Rev Neurol 4 (suppl 4) : S3-10, 2004
 
12) Tsuchiya K, Katase S, Yoshino A : FLAIR MR imaging for diagnosing intracranial meningeal carcinomatosis. AJR 176 : 1585-8, 2001
PubMed
13) Glantz MJ, Cole BF, Glantz LK : cerebrospinal fluid cytology in patients with cancer : minimizing false-negative results. Cancer 82 : 733-9, 1998
PubMed
14) Shukuya T, Takahashi T, Naito T : Continuous EGFR-TKI administration following radiotherapy for non-small lung cancer patients with isolated CNS failure. Lung Cancer 74 : 457-61, 2011
PubMed
15) Bleyer WA, Poplack DG, Simon RM : "Concentration x time" methotrexate via a subcutaneous reservoir : a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51 : 835-42, 1978
 
16) Berg SL, Chamberlain MC : Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep 5 : 29-40, 2003
PubMed
17) 高橋英樹, 吉田誠一 : 固形がんにおける髄膜がん腫症の臨床. 新潟がんセンター病院医誌 52 : 60-6, 2013
 
18) 奥田武司, 片岡和夫, 加藤天美 : 胃がん原発の髄膜がん腫症における治療検討. がんと化学療法 36 : 599-603, 2009
 
19) 三矢幸一, 中洲庸子, 溝上義人 : 肺腺がんのがん性髄膜症に対する EGFR-TKI, VPシャント, 放射線治療による集学的治療. 脳神経外科 40 : 503-9, 2012
 

第5章 中枢神経系のがん救急

P.102 掲載の参考文献
1) Lewis MA, Hendrickson AW, Moynihan TJ : Oncologic emergencies : Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 61 : 287-314, 2011
PubMed
2) 成田善孝 : 頭蓋内圧亢進, 10-4 (大江裕一郎, 新海哲, 高橋俊二 : がん救急マニュアル. メディカルビュー社, 東京, 2011)
 
3) 高橋英明 : 総説「固形癌における髄膜癌腫症の臨床」. 県立がんセンター新潟病院医誌 52 : 60-6, 2013
 
4) 成田善孝, 渋井壮一郎 : 脳神経脊髄症状に対する緊急処置. がんと化学療法 35 : 2301-6, 2008
 
5) 高橋英明 : 総説 担癌患者の脳梗塞. 新潟県医師会報 713 : 2-5, 2009
 

第6章 がん種別における転移性脳腫瘍の特徴

P.110 掲載の参考文献
1) Japan Tcobtro : Report of brain tumor registry of Japan (2001-2004). Neurologia medicochirurgica 54 (Suppl 1), 2014
 
2) Sperduto PW, Kased N, Roberge D, et al : Summary report on the graded prognostic assessment : an accurate and facile diagnosisspecific tool to estimate survival for patients with brain metastases. J Clin Oncol 30 : 419-25, 2012
PubMed
3) Davies MA : Targeted therapy for brain metastases. Adv Pharmacol 65 : 109-42, 2012
PubMed
4) Ettinger DS, Akerley W, Borghaei H, et al : Nonsmall cell lung cancer, version 2. J Natl Compr Canc Netw 11 : 645-53, quiz 53, 2013
 
5) Soffietti R, Trevisan E, Ruda R : Targeted therapy in brain metastasis. Curr Opin Oncol 24 : 679-86, 2012
PubMed
6) Ceresoli GL, Cappuzzo F, Gregorc V, et al : Gefitinib in patients with brain metastases from non-small-cell lung cancer : a prospective trial. Ann Oncol 15 : 1042-7, 2004
PubMed
7) Chiu CH, Tsai CM, Chen YM, et al : Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47 : 129-38, 2005
PubMed
8) Hotta K, Kiura K, Ueoka H, et al : Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46 : 255-61, 2004
PubMed
9) Namba Y, Kijima T, Yokota S, et al : Gefitinib in patients with brain metastases from non-smallcell lung cancer : review of 15 clinical cases. Clin Lung Cancer 6 : 123-8, 2004
 
10) Wu C, Li YL, Wang ZM, et al : Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57 : 359-64, 2007
 
11) Altavilla G, Arrigo C, Santarpia MC, et al : Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases. J Neurooncol 90 : 31-3, 2008
 
12) Bai H, Han B : The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. Am J Clin Oncol 36 : 110-5, 2013
PubMed
13) Fekrazad MH, Ravindranathan M, Jones DV, Jr. : Response of intracranial metastases to erlotinib therapy. J Clin Oncol 25 : 5024-6, 2007
PubMed
14) Lai CS, Boshoff C, Falzon M, et al : Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 61 : 91, 2006
PubMed
15) Popat S, Hughes S, Papadopoulos P, et al : Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. Lung Cancer 56 : 135-7, 2007
PubMed
16) Porta R, Sanchez-Torres JM, Paz-Ares L, et al : Brain metastases from lung cancer responding to erlotinib : the importance of EGFR mutation. Eur Respir J 37 : 624-31, 2011
PubMed
17) Kim JE, Lee DH, Choi Y, et al : Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65 : 351-4, 2009
PubMed
18) Eichler AF, Kahle KT, Wang DL, et al : EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 12 : 1193-9, 2010
PubMed
19) Masuda T, Hattori N, Hamada A, et al : Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 67 : 1465-9, 2011
PubMed
20) Kwak EL, Bang YJ, Camidge DR, et al : Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 : 1693-703, 2010
PubMed
21) Costa DB, Kobayashi S, Pandya SS, et al : CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29 : e443-5, 2011
PubMed
22) Seute T, Leffers P, ten Velde GP, et al : Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 100 : 801-6, 2004
PubMed
23) Nugent JL, Bunn PA, Jr., Matthews MJ, et al : CNS metastases in small cell bronchogenic carcinoma : increasing frequency and changing pattern with lengthening survival. Cancer 44 : 1885-93, 1979
PubMed
24) Kalemkerian GP, Akerley W, Bogner P, et al : Small cell lung cancer. J Natl Compr Canc Netw 11 : 78-98, 2013
PubMed
25) Auperin A, Arriagada R, Pignon JP, et al : Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.N Engl J Med 341 : 476-84, 1999
 
26) Slotman B, Faivre-Finn C, Kramer G, et al : Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 : 664-72, 2007
PubMed
27) Kennecke H, Yerushalmi R, Woods R, et al : Metastatic behavior of breast cancer subtypes. J Clin Oncol 28 : 3271-7, 2010
PubMed
28) Stemmler HJ, Schmitt M, Willems A, et al : Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18 : 23-8, 2007
PubMed
29) Oliveira M, Braga S, Passos-Coelho JL, et al : Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 127 : 841-4, 2011
 
30) Perissinotti AJ, Reeves DJ : Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother 44 : 1633-40, 2010
PubMed
31) Stemmler HJ, Schmitt M, Harbeck N, et al : Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15 : 1373-7, 2006
PubMed
32) Brufsky AM, Mayer M, Rugo HS, et al : Central nervous system metastases in patients with HER2-positive metastatic breast cancer : incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17 : 4834-43, 2011
PubMed
33) Dawood S, Gonzalez-Angulo AM, Albarracin C, et al : Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy : a single-institution review. Cancer 116 : 3084-92, 2010
PubMed
34) Le Scodan R, Jouanneau L, Massard C, et al : Brain metastases from breast cancer : prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 11 : 395, 2011
PubMed
35) Okita Y, Narita Y, Suzuki T, et al : Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Mol Clin Oncol 1 : 995-1001, 2013
PubMed
36) Xu Z, Marko NF, Chao ST, et al : Relationship between HER2 status and prognosis in women with brain metastases from breast cancer. Int J Radiat Oncol Biol Phys 82 : e739-47, 2012
PubMed
37) Bogina G, Bortesi L, Marconi M, et al : Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours : clinical implications of progesterone receptor loss. Virchows Arch 459 : 1-10, 2011
PubMed
38) Broom RJ, Tang PA, Simmons C, et al : Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time : discordance rates between primary and metastatic breast cancer. Anticancer Res 29 : 1557-62, 2009
PubMed
39) Guarneri V, Giovannelli S, Ficarra G, et al : Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases : impact on patient management. Oncologist 13 : 838-44, 2008
PubMed
40) Nishimura R, Osako T, Okumura Y, et al : Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer : discordance rates and prognosis. World J Surg Oncol 9 : 131, 2011
PubMed
41) Yonemori K, Tsuta K, Shimizu C, et al : Immunohistochemical profiles of brain metastases from breast cancer. J Neurooncol 90 : 223-8, 2008
PubMed
42) Bachelot T, Romieu G, Campone M, et al : Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE) : a single-group phase 2 study. Lancet Oncol 14 : 64-71, 2013
PubMed
43) Vogl UM, Zehetgruber H, Dominkus M, et al : Prognostic factors in metastatic renal cell carcinoma : metastasectomy as independent prognostic variable. Br J Cancer 95 : 691-8, 2006
PubMed
44) Wronski M, Maor MH, Davis BJ, et al : External radiation of brain metastases from renal carcinoma : a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37 : 753-9, 1997
 
45) Nieder C, Spanne O, Nordoy T, et al : Treatment of brain metastases from renal cell cancer. Urol Oncol 29 : 405-10, 2011
PubMed
46) Gore ME, Hariharan S, Porta C, et al : Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117 : 501-9, 2011
PubMed
47) Pouessel D, Culine S : High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53 : 376-81, 2008
PubMed
48) Ettinger DS, Handorf CR, Agulnik M, et al : Occult primary, version 3. 2014. J Natl Compr Canc Netw 12 : 969-74, 2014
PubMed
49) Hemminki K, Riihimaki M, Sundquist K, et al : Site-specific survival rates for cancer of unknown primary according to location of metastases. Int J Cancer 133 : 182-9, 2013
PubMed
50) Polyzoidis KS, Miliaras G, Pavlidis N : Brain metastasis of unknown primary : a diagnostic and therapeutic dilemma. Cancer Treat Rev 31 : 247-55, 2005
PubMed
51) Riihimaki M, Hemminki A, Sundquist K, et al : Time trends in survival from cancer of unknown primary : small steps forward. Eur J Cancer 49 : 2403-10, 2013
PubMed
52) Hess KR, Varadhachary GR, Taylor SH, et al : Metastatic patterns in adenocarcinoma. Cancer 106 : 1624-33, 2006
PubMed
53) Velander AJ, DeAngelis LM, Navi BB : Intracranial hemorrhage in patients with cancer. Curr Atheroscler Rep 14 : 373-81, 2012
PubMed
54) Kim M, Na DL, Park SH, et al : Nervous system involvement by metastatic hepatocellular carcinoma. J Neurooncol 36 : 85-90, 1998
 
55) Han MS, Moon KS, Lee KH, et al : Brain metastasis from hepatocellular carcinoma : the role of surgery as a prognostic factor. BMC Cancer 13 : 567, 2013
PubMed
56) Choi HJ, Cho BC, Sohn JH, et al : Brain metastases from hepatocellular carcinoma : prognostic factors and outcome : brain metastasis from HCC. J Neurooncol 91 : 307-13, 2009
PubMed
57) Bryant BM, Wiltshaw E : Central nervous system involvement in sarcoma. A presentation of 12 cases, a review of the literature, and a discussion of possible changing patterns with the use of chemotherapy, placing special emphasis on embryonal tumours. Eur J Cancer 16 : 1503-7, 1980
 
58) Gercovich FG, Luna MA, Gottlieb JA : Increased incidence of cerebral metastases in sarcoma patients with prolonged survival from chemotherapy. Report of cases of leiomysarcoma and chondrosarcoma. Cancer 36 : 1843-51, 1975
PubMed
59) Graus F, Walker RW, Allen JC : Brain metastases in children. J Pediatr 103 : 558-61, 1983
 
60) Espana P, Chang P, Wiernik PH : Increased incidence of brain metastases in sarcoma patients. Cancer 45 : 377-80, 1980
PubMed
61) Wronski M, Arbit E, Burt M, et al : Resection of brain metastases from sarcoma. Ann Surg Oncol 2 : 392-9, 1995
PubMed
62) Ogose A, Morita T, Hotta T, et al : Brain metastases in musculoskeletal sarcomas. Jpn J Clin Oncol 29 : 245-7, 1999
PubMed
63) Fox BD, Patel A, Suki D, et al : Surgical management of metastatic sarcoma to the brain. J Neurosurg 110 : 181-6, 2009
 
64) Besse B, Lasserre SF, Compton P, et al : Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16 : 269-78, 2010
PubMed
65) Khasraw M, Holodny A, Goldlust SA, et al : Intracranial hemorrhage in patients with cancer treated with bevacizumab : the Memorial Sloan-Kettering experience. Ann Oncol 23 : 458-63, 2012
PubMed

第7章 転移性脳腫瘍の緩和医療

P.121 掲載の参考文献
1) 志真泰夫, 恒藤暁, 荒尾晴恵 : 緩和ケアの歴史と展望, 5 (日本緩和医療学会編 : 専門家をめざす人のための緩和医療学. 南江堂, 東京, 2014)
 
2) 山崎章郎, 米沢慧 : ホスピスケアの定義, 94 (新ホスピス宣言. 雲母書房, 東京, 2006)
 
3) Chow E, Fan G, Hadi S, et al : Symptom Clusters in Cancer Patients with Brain Metastases. Clinical Oncology 20 : 76-82, 2008
 
4) Breitbart W, Gibson C, Tremblay A : The delirium experience : delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 43 : 183-94, 2002
PubMed
5) 稲田修士, 吉内一浩 : 転移性脳腫瘍 精神腫瘍学に関する問題点と対応, 292 (内富庸介, 小川朝生編 : 精神腫瘍学. 医学書院, 東京, 2011)
 
6) 足立誠司, 安部睦美 : 痛みの包括的評価, 33 (日本緩和医療学会 緩和医療ガイドライン委員会編 : がん疼痛の薬物療法に関するガイドライン2014年版. 金原出版, 東京, 2014)
 
7) 鄭陽, 二見典子, 山本亮, 他 : 包括的アセスメント, 58-9 (日本緩和医療学会編 : 専門家をめざす人のための緩和医療学. 南江堂, 東京, 2014)
 
8) Miyashita M, Yasuda M, Baba R, et al : Interrater reliability of proxy simple symptom assessment scale between physician and nurse : A hospital-based palliative care team setting. Eur J Cancer Care 19, 124-30, 2010
 
9) 森田達也 : ホスピスケアと緩和ケア : 失ってはならないものと変わっていかなければならないもの. 日本緩和医療学会 News Letter 18 : 203, 2003
 
10) 高瀬久光, 細谷治, 赤木徹, 他 : オピオイドに与える影響・薬理相互作用, 63 (日本緩和医療学会 緩和医療ガイドライン委員会編 : がん疼痛の薬物療法に関するガイドライン2014年版. 金原出版, 東京, 2014)
 
11) 龍恵美, 久原幸 : 非オピオイド鎮痛薬, 鎮痛補助薬, 74-82 (日本緩和医療学会 緩和医療ガイドライン委員会編 : がん疼痛の薬物療法に関するガイドライン2014年版. 金原出版, 東京, 2014)
 
12) Stepanski EJ, Walker MS, Schwartzberg LS, et al : The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med 15 : 132-6, 2009
 

第8章 転移性脳腫瘍の治療指針

P.131 掲載の参考文献
1) National Comprehensive Cancer Network Guidelines for Treatment of Cancer by Site. www.nccn.org/professionals/physician_gls/
 
2) Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastases (es) : An American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncology 2 : 210-225, 2012
PubMed
3) Feyer P, Sautter-Bihl ML, Budach W, et al. DEGRO practical guidelines for palliative radiotherapy of breast cancer patients : Brain metastases and Leptomeningeal Carcinomatosis. Strahlenther Onkol 86 : 63-69, 2010
 
4) Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis ( RPA) of prognostic factors in thee Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997 ; 37 (4) : 745-51
 
5) Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment : an accurate and facile diagnosis specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012 : 30 : 419-425
 
6) Ahn HK, Lee S, Park YH, et al. Prediction of outcomes for patients with brain parenchymal metastases from breast cancer : a new BCspecific prognostic model and a nomogram. NeuroOncology 2012 : 14 : 1105-1113
 
7) Nieder C, Mehta MP. Prognostic indices for brain metastases : usefulness and challenges. Radiat Oncol. 2009 ; 4 : 10
PubMed
8) 浜田知久馬 : 学会論文のための統計学, 真興交易医書出版部, 2012
 
P.135 掲載の参考文献
1) Markesbery WR, Brooks WH, Gupta GD, et al : Treatment for patients with cerebral metastases. Arch Neurol 35 : 754-6, 1978
PubMed
2) Ruderman NB, Hall TC : Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer 18 : 298-306, 1965
PubMed
3) Bindal RK, Sawaya R, Leavens ME, et al : Surgical treatment of multiple brain metastases. J Neurosurg 79 : 210-6, 1993
PubMed
4) Patchel RR, Tibbs PA, Walsh JW, et al : A randomized trial of surgery in the treatment of single metastases to the brain. NEJM 322 : 494-500, 1990
 
5) Alexander E 3rd, Moriarty TM, Davis RB, et al : Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87 : 34-40, 1995
PubMed
6) Gaspar L, Scott C, Rotman M, et al : Recursive partitioning analysis (RPA) of prognostic factors in thee Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 : 745-51, 1997
 
7) Sperduto PW, Kased N, Roberge D, et al : Summary report on the graded prognostic assessment : an accurate and facile diagnosis specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30 : 419-25, 2012
PubMed
P.136 掲載の参考文献
1) Karnofsky DA, Burchenal JH, Armistead GC Jr, et al : Triethylene melamine in the treatment of neoplastic disease ; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use. Arch Intern Med 87 : 477-516, 1951
PubMed
2) JCOGホームページ http://www.jcog.jp/doctor/tool/ps.html
 
P.138 掲載の参考文献
1) Hinchey J, Chaves C, Appignani B : A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 : 494-500, 1996
 
2) Glantz MJ, Cole BF, Glantz LK : cerebrospinal fluid cytology in patients with cancer : minimizing false-negative results. Cancer 82 : 733-9, 1998
PubMed
P.139 掲載の参考文献
1) Mitsuya K, Nakasu Y : Metastatic Skull Tumours : Diagnosis and Management. EANO Mag 4 : 71-4, 2014
 
P.144 掲載の参考文献
1) 志真泰夫, 恒藤暁, 荒尾晴恵 : 緩和ケアの歴史と展望, 5 (日本緩和医療学会編 : 専門家をめざす人のための緩和医療学. 南江堂, 東京, 2014)
 
P.146 掲載の参考文献
1) 加藤伸司, 下垣光, 小野寺敦志, 他 : 改訂 長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精神医学雑誌 2 : 1339-47, 1991
Medical*Online
2) Folstein MF, Folstein SE, McHugh PR : Mini mental state : A practical method for grading the cognitive state of patients for clinician. J Psychiat Res 12 : 189-98, 1975
 
P.147 掲載の参考文献
1) Barnholtz-Sloan JS, Sloan AE, Davis FG, et al : Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 : 2865-72, 2004
PubMed
2) Hojo S, Hirano A : Pathology of metastases affecting the central nervous system, 5-111, (Takakura K, Sano K, Hojo S, Hirano A, eds : Metastatic tumors of the central nervous system. Igaku-Shoin, Tokyo, 1982)
 
3) Macdonald DR, Cascino TL, Schold SC, Jr., et al : Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-80, 1990
PubMed
4) Jaffe CC : Measures of response : RECIST, WHO, and new alternatives. J Clin Oncol 24 : 3245-51, 2006
PubMed
5) Patchel RR, Tibbs PA, Walsh JW, et al : A randomized trial of surgery in the treatment of single metastases to the brain. NEJM 322 : 494-500, 1990
 
6) Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al : Treatment of single brain metastasis : radiotherapy alone or combined with neurosurgery? Ann Neurol 33 : 583-90, 1993
 
7) Mintz AH, Kestle J, Rathbone MP, et al : A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78 : 1470-6, 1996
PubMed
8) Andrews DW, Scott CB, Sperduto PW, et al : Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases : phase III results of the RTOG 9508 randomised trial. Lancet. 363 : 1665-72, 2004
PubMed
9) Aoyama H, Shirato H, Tago M, et al : Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases : a randomized controlled trial. JAMA 295 : 2483-91, 2006
PubMed
10) Muacevic A, Wowra B, Siefert A, et al : Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain : a randomized controlled multicentre phase III trial. J Neurooncol 87 : 299-307, 2008
 
11) Kocher M, Soffietti R, Abacioglu U, et al : Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study. J Clin Oncol 29 : 134-41, 2011
 
12) Yamamoto M, Serizawa T, Shuto T, et al : Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901) : a multi-institutional prospective observational study. Lancet Oncol 15 : 387-95, 2014
 
13) Aoyama H, Tago M, Kato N, et al : Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68 : 1388-95, 2007
PubMed
14) Soffietti R, Kocher M, Abacioglu UM, et al : A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery : quality-of-life results. J Clin Oncol 31 : 65-72, 2013
PubMed
15) Gaspar L, Scott C, Rotman M, et al : Recursive partitioning analysis (RPA) of prognostic factors in thee Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 : 745-51, 1997
 
16) Sperduto PW, Kased N, Roberge D, et al : Summary report on the graded prognostic assessment : an accurate and facile diagnosis specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30 : 419-25, 2012
PubMed
17) Bindal RK, Sawaya R, Leavens ME, et al : Surgical treatment of multiple brain metastases. J Neurosurg 79 : 210-6, 1993
PubMed
P.151 掲載の参考文献
1 National Comprehensive Cancer Network Guidelines for Treatment of Cancer http://www.nccn.org/professionals/physician_gls/
 
2 国立がん研究センターの情報サービス ganjoho.jp/public/index.html
 
3 日本臨床腫瘍研究グループ (JCOG) ホームページ http://www.jcog.jp/
 
4 Chemocare. com http://www.chemocare.com
 

書評

最近チェックした商品履歴

Loading...